Sherbrooke Park Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sherbrooke Park Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,652	Closed	-$739K	–	233
2025 Q3	$739K	Sell	13,652 -11,026	-45%	-$631K	0.34%	75
2025 Q2	$1.36M	Buy	+24,678	New	+$1.45M	0.59%	11
2025 Q1	–	Sell	-5,510	Closed	-$362K	–	632
2024 Q4	$362K	Buy	+5,510	New	+$369K	0.12%	319
2024 Q3	–	Sell	-7,488	Closed	-$616K	–	930
2024 Q2	$616K	Buy	7,488 +2,820	+60%	+$235K	0.11%	322
2024 Q1	$408K	Buy	+4,668	New	+$418K	0.08%	440
2023 Q4	–	Sell	-12,515	Closed	-$1.11M	–	472
2023 Q3	$1.11M	Buy	+12,515	New	+$1.11M	0.35%	86

Other funds holding BMRN

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return